A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

Lynn G Feun, J. A. Blessing, R. J. Barrett, P. Hanjani

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.

Original languageEnglish
Pages (from-to)506-508
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number6
StatePublished - Jan 1 1993

Fingerprint

triciribine phosphate
Nucleosides
Cervix Uteri
Squamous Cell Carcinoma
Phosphates
Appointments and Schedules
Squamous Cell Neoplasms
Hypocalcemia
Uterine Cervical Neoplasms
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{bf44b70a8b10472fa8185e68acbc2db3,
title = "A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study",
abstract = "A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.",
author = "Feun, {Lynn G} and Blessing, {J. A.} and Barrett, {R. J.} and P. Hanjani",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "16",
pages = "506--508",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix

T2 - A Gynecologic Oncology Group study

AU - Feun, Lynn G

AU - Blessing, J. A.

AU - Barrett, R. J.

AU - Hanjani, P.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.

AB - A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.

UR - http://www.scopus.com/inward/record.url?scp=0027333359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027333359&partnerID=8YFLogxK

M3 - Article

C2 - 8256767

AN - SCOPUS:0027333359

VL - 16

SP - 506

EP - 508

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -